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Abstract: Terbium-149 is among the most interesting therapeutic nuclides for medical 
applications. It decays by emission of short-range α-particles (Eα = 3.967 MeV) with a  
half-life of 4.12 h. The goal of this study was to investigate the anticancer efficacy of a 
149
Tb-labeled DOTA-folate conjugate (cm09) using folate receptor (FR)-positive cancer 
cells in vitro and in tumor-bearing mice. 
149
Tb was produced at the ISOLDE facility at 
CERN. Radiolabeling of cm09 with purified 
149
Tb resulted in a specific activity of ~1.2 
MBq/nmol. In vitro assays performed with 
149
Tb-cm09 revealed a reduced KB cell 
viability in a FR-specific and activity concentration-dependent manner. Tumor-bearing mice 
were injected with saline only (group A) or with 
149
Tb-cm09 (group B: 2.2 MBq; group C: 
3.0 MBq). A significant tumor growth delay was found in treated animals resulting in an 
increased average survival time of mice which received 
149
Tb-cm09 (B: 30.5 d; C: 43 d) 
compared to untreated controls (A: 21 d). Analysis of blood parameters revealed no signs 
of acute toxicity to the kidneys or liver in treated mice over the time of investigation.  
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These results demonstrated the potential of folate-based α-radionuclide therapy in  
tumor-bearing mice. 
Keywords: terbium-149; alpha-therapy; folate receptor; DOTA-folate; KB tumors;  
149
Tb-cm09; albumin binder, radionuclide therapy 
 
1. Introduction 
Targeted radionuclide therapy using β−-particle-emitting radionuclides (e.g., 131I, 90Y, 177Lu) of variable 
energies is employed in clinical routine. For this purpose a variety of tumor-targeted biomolecules 
have been used, ranging from small-molecular weight compounds (e.g., 
131
I-MIBG), to peptides  
(e.g., 
177
Lu-DOTATATE) and monoclonal antibodies (
90
Y-Ibritumomab, Zevalin
®
) [1,2]. A promising 
option for a potential improvement of the therapeutic efficacy of radioendotherapy may be the 
selection of appropriate radionuclides. α-Particles of medically interesting radionuclides provide a 200- 
to 1,000-fold higher linear energy transfer (LET) than β−-particles [3,4]. Therefore, and because of the 
much shorter path-length (25–100 μm) of α-particles compared to β−-particles (0.05–12 mm),  
α-particle-emitting nuclides may be interesting for targeted radionuclide therapy of micrometastases or 
even single cancer cells. 
Allen et al. suggested the radiolanthanide 
149
Tb as the preferred radionuclide for α-radionuclide 
therapy [3]. A decay scheme with a list of significant emitted radiation of 
149
Tb and its daughter 
nuclides has been previously published by Beyer et al. [5]. 
149
Tb decays with a half-life of 4.12 h by 
emission of short-range α-particles (Eα = 3.967 MeV, I = 16.7%) [4,5]. In addition, it emits γ-rays of 
an energy (Eγ = 165 keV, 26.4%) potentially suitable for single photon emission computed tomography 
(SPECT) and positrons (Eβ+ average = 638 keV, 3.8%) which may be detected via positron emission 
tomography (PET) (Figure 1A) [4,6]. However, there also exists suitable diagnostic matched nuclides 
such as 
155
Tb (T1/2 = 5.32 d, Eγ= 87 keV, I = 32% and 105 keV, I = 25%) and 
152
Tb (T1/2 = 17.5 h,  
Eβ+ average = 1.08 MeV, I = 17%) for imaging purposes via SPECT and PET, respectively [7]. Tb can be 
stably coordinated by macrocyclic chelators (e.g., DOTA) as it has been recently demonstrated using 
the β−-emitting nuclide 161Tb [7–9]. 149Tb is among the most attractive candidates of α-emitting 
radiometals for targeted radionuclide therapy. Other α-emitters have either a very short half-life  
(
213
Bi: T1/2 = 46 min, 
212
Bi: T1/2 = 61 min) or a complicated decay cascade of 4 to 5 α-emissions  
(
225
Ac: T1/2 = 10.0 d, 
227
Th: T1/2 = 18.7 d) [4,10,11]. The longer-lived in vivo generator 
212
Pb/
212
Bi  
(T1/2 = 10.64 h) might be a more favorable solution but could suffer from release of the 
212
Bi from the 
DOTA complex [12]. In such cases the decay of the daughter nuclides may occur in non-targeted 
organs which could cause undesired toxicity to healthy tissue [13]. In spite of the fact that the α-emitting 
211
At (T1/2 = 7.21 h) is considered appropriate for medical use with regard to the physical properties, a 
major impediment to practical applications is the low in vivo stability of astatine bonds with aromatic 
carbon bonds [14]. However, current availability of 
149
Tb is poor due to production routes which are not 
easily accessible [6]. Potential production routes include irradiation of rare 
152
Gd targets with high 
energy protons (>50 MeV) or the use of light ions as projectiles of >500 MeV protons for spallation 
reactions. However, in both cases mass separation is required to avoid radioisotopic impurities. 
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Figure 1. (A) The α-particle-emitting 149Tb as one of four medically interesting  
terbium-nuclides which belong to the series of chemical elements called lanthanides  
(15 elements from La to Lu); (B) Chemical structure of the radiolabeled DOTA-folate 
conjugate (cm09) with an albumin binding entity (speculative coordination sphere of the 
Tb-DOTA-complex). 
 
The aim of the present study was to complement our preliminary in vivo results [7] by a further 
study using 
149
Tb for in vitro cell viability assays and in vivo using a well-established tumor mouse 
model. We employed the recently developed DOTA-folate conjugate (herein referred to as cm09, 
Figure 1B) and human KB cancer cells which express the folate receptor (FR) at high levels. From our 
previous in vivo studies performed with 
177
Lu-cm09, it is known that the novel folate radioconjugate is 
applicable for preclinical therapy studies in the KB tumor mouse model where it provides an excellent 
tumor accumulation of radioactivity and as a consequence high antitumor efficacy [15]. 
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2. Experimental 
2.1. Chemicals and Reagents for Production and Purification of 
149
Tb 
Gold foils (thickness: 0.1 mm, purity: 99.95%, Goodfellow Cambridge Ltd. Huntingdon, UK) were 
electrolytically coated with a thin layer of zinc (purity ≥99.9%). The acids in this work (HNO3 
suprapur and HCl suprapur) were obtained from VWR International GmbH (Dietikon, Switzerland) 
and diluted with MilliQ water (18.2 MΩ·cm; Millipore AG, Zug, Switzerland). A solution  
of NH3 (25%, suprapur) was obtained from VWR International GmbH. α-Hydroxyisobutyric acid  
(α-HIBA, purity: 99%), L-lactic acid (C3H6O3, purity ≥99%) and NaOH monohydrate (Traceselect, 
purity ≥99.9995%) were obtained from Sigma-Aldrich International GmbH (St. Gallen, Switzerland). 
2.2. Production of 
149
Tb 
149
Tb was produced at the isotope separation online facility ISOLDE (CERN, Geneva, Switzerland) 
as previously reported [7,16,17]. In brief, a tantalum target (50 g/cm
2
) was irradiated with high-energy 
(~1.4 GeV) protons. After effusion of the spallation products from the heated target (~2,000 °C) they 
were ionized by surface ionization and resonant laser ionization. The monocations were extracted from 
the ion source, accelerated to 50 keV and separated in a magnetic field according to their mass [16,17]. 
Products of mass number 149 were implanted into a zinc-coated gold foil (70 mm
2
) and shipped to PSI 
for the purification procedure. 
2.3. Purification of 
149
Tb 
The zinc layer was dissolved in a solution mixture of HNO3/NH4NO3 (0.2 M NO3
−
, pH 1, 500 μL) 
at 50 °C. Isolation of 
149
Tb from isobar and pseudo-isobar impurities and stable Zn was accomplished 
by cation exchange chromatography. For this purpose a column (5 mm × 35 mm) filled with a strongly 
acidic macroporous cation exchange resin was employed as recently reported [7,18]. 
149
Tb and 
149
Gd 
were eluted with α-HIBA (0.13 M) at a flow rate of 0.33 mL/min allowing their separation [7]. Further 
radioactive impurities and stable Zn remained on the column. Regeneration of the column was carried 
out using higher concentrated α-HIBA (1.0 M). The collected fractions (330 μL each) which contained 
149
Tb-α-HIBA were acidified by addition of HCl (4 M, 17 μL). The acidic solution was loaded on a 
second cation exchange chromatography column (4 mm × 4 mm). α-HIBA, NH4
+
 and HCl were 
removed by a washing step using MilliQ water. The elution of 
149
Tb was performed by a solution of  
L-lactate (0.4 M) previously adjusted to a pH value of 4.7 with sodium hydroxide. The eluted  
149
Tb-fraction was diluted with the 1.7-fold volume of MilliQ water to adjust the osmolarity to a 
physiological value (~300 mOsm). 
2.4. Preparation of 
149
Tb-cm09 and Stability in Blood Plasma 
Radiolabeling was performed by addition of 18 μL of the DOTA-folate (cm09) stock solution  
(10 mM, corresp. to 18 nmol of cm09) to the obtained solution of 
149
Tb (25 MBq) in L-lactate  
(pH 4.7). The reaction mixture was incubated for 10 min at 95 °C. Quality control was performed by 
HPLC using a C-18 reversed phase column (Xterra MS C-18, 5 μm, 15 cm × 4.6 cm, Waters, Milford, 
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MA, USA). The mobile phase consisted of MilliQ water with 0.1% trifluoroacetic acid (A) and 
methanol (B) with a linear gradient from 5% to 80% B over 25 min at a flow rate of 1 mL/min.  
The product (Rt = 19.5 min) was obtained with a radiochemical purity of >96%. After addition of  
Na-DTPA (10 μL, 5 mM, pH 5) the labeling solution (1.0–1.2 MBq/nmol) was directly used for  
in vitro and in vivo application. The stability of 
149
Tb-cm09 was investigated by incubation of the 
radioconjugate (50 μL, ~1 MBq) in human plasma (250 μL) at 37 °C. Aliquots (50 μL) were taken for 
analysis after 30 min, 1 h and 4 h. The proteins were precipitated by addition of methanol (200 μL) and 
the supernatants were analyzed using HPLC. 
2.5. Cell Culture 
KB cells (human cervical carcinoma cell line, HeLa subclone; ACC-136) were purchased from the 
German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany). Cells 
were cultured as monolayers at 37 °C in a humidified atmosphere containing 5% CO2. Importantly KB 
cells were cultured in a folate-free special cell culture medium, FFRPMI (modified RPMI, without 
folic acid, vitamin B12 and phenol red; Cell Culture Technologies GmbH, Gravesano/Lugano, 
Switzerland). FFRPMI media was supplemented with 10% heat-inactivated fetal calf serum (FCS),  
L-glutamine and antibiotics (penicillin/streptomycin/fungizone). Routine culture treatment was 
performed twice a week. 
2.6. In Vitro Cell Viability Studies 
Inhibition of KB cell viability was investigated using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay [19]. The cells were harvested and seeded in 96-well plates 
at 2.5 × 10
3
 cells per well in a final volume of 200 μL FFRPMI medium with supplements. After 24 h 
incubation for cell adhesion, the medium was removed and the cells were incubated with 
149
Tb-cm09 
(0.05–500 kBq in 200 μL medium/well) alone or in combination with excess folic acid (200 nM) for  
4 h at 37 °C. Cell incubation with FFRPMI medium only was performed as a control experiment.  
After incubation, the supernatants were removed and KB cells were washed with PBS (200 μL/well) 
before addition of supplemented FFRPMI medium (200 μL/well). Cells were then allowed to grow  
for 4 days before analysis as previously reported [20]. After addition of 30 μL of an MTT solution  
(5 mg/mL) to each well, the well-plates were incubated for an additional 4 h at 37 °C. The medium 
was removed and the dark-violet formazan crystals were dissolved in dimethyl sulfoxide. The 
absorbance was determined at 560 nm using a microplate reader (Victor X3, Perkin Elmer, Waltham, 
MA, USA). To quantify cell viability, the ratio of the absorbance of the test samples to the absorbance 
of control cell samples (=100% viability) was calculated using Microsoft Excel software (Microsoft 
Corp. Redmond, WA, USA). 
2.7. In Vivo Therapy Studies 
In vivo experiments were approved by the local veterinary department and conducted in accordance 
with the Swiss law of animal protection. Four to five-week-old female, athymic nude mice (CD-1 
Foxn-1/nu) were purchased from Charles River Laboratories (Sulzfeld, Germany). They were fed with 
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a folate-deficient rodent diet (ssniff Spezialdiäten GmbH, Soest, Germany) starting 5 days prior to 
tumor cell inoculation [21]. Endpoint criteria were defined as weight loss of >15% of the initial body 
weight (at day 0), tumor volume >1,000 mm
3
, ulceration or bleeding of the tumor xenograft or 
abnormal behavior indicating pain or unease of the animal. 
The therapy study was performed according to the injection protocol shown in Table 1. Twelve 
mice were subcutaneously inoculated with 5 × 10
6
 KB tumor cells (suspended in 100 μL PBS) as 
previously reported 4 days before injection of the radioactive folate conjugate [15]. 
Table 1. Injection protocol of the in vivo therapy study. 
 Number of mice [n] Injection solution Injected radioactivity [MBq] 
Group A 4 L-lactate solution - 
Group B 4 149Tb-cm09 in L-lactate solution 2.2 
Group C 4 149Tb-cm09 in L-lactate solution 3.0 
At the time of treatment the tumors reached a volume 60–80 mm3. Mice of group A were 
intravenously injected with only L-lactate solution whereas mice of group B and C received  
149
Tb-cm09 (2.2 MBq and 3.0 MBq, respectively) in the same L-lactate solution. The amount of 
injected activity was the highest possible based on the availability of the nuclide sufficient to inject 4 
mice. After start of the therapy mice were weighed three times a week over 35 days and tumor 
volumes were monitored by measuring two perpendicular diameters with a caliper and calculated 
according to the equation: V = 0.5 × L × W
2
 (L is the length (large diameter) and W is the width (small 
diameter) of the tumor). Mice were removed from the study if one or several of the predefined 
endpoint criteria were reached which required euthanasia. 
The therapeutic efficacy was expressed as the percentage of tumor growth inhibition (%TGI) 
calculated according to the formula: %TGI = 100 − (RTVT/RTVU × 100), where RTVT is the mean 
relative tumor volume of treated mice (groups B or C), and RTVU is the mean relative tumor volume 
of untreated mice (group A) determined at day 21 when the first control mouse was euthanized. The 
tumor growth delay index (TGDI) was calculated according to the formula: TGDI = TGDT/TGDU.  
It was defined as the mean tumor growth delay ratio of treated (TGDT) and untreated animals (TGDU) 
which was required to increase the RTV 5-fold [22]. 
2.8. Determination of Plasma Parameters 
Plasma parameters such as blood urea nitrogen (BUN), alkaline phosphatase (ALP), and total 
bilirubin (TBIL) were measured from all mice at day 14 after start of the therapy and before euthanasia 
of each mouse. BUN is a common parameter to determine potential damage to the kidneys whereas 
increased ALP and TBIL could be an indication for impaired liver function. Plasma samples were 
prepared by centrifugation of blood samples (150–200 μL per mouse) drawn from the sublingual vein 
of each mouse and collected in heparinized vials (Microvette, 200 mL Sarstedt, Nümbrecht, Germany). 
For each parameter a plasma volume of 10 μL was required for the analysis using a Fuji Dri-Chem 
40000i analyzer (Polymed Medical Center AG, Glattbrugg, Switzerland). 
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2.9. Dosimetric Calculations 
To estimate the equivalent absorbed dose for 
149
Tb-cm09 in KB tumor xenografts, biodistribution 
data obtained with 
161
Tb-cm09 were used. Based on these data the following calculations were made: 
(i) the cumulative radioactivity was calculated from integrated AUCs (MBq·s) of biodistribution data 
expressed in non decay-corrected percent injected activity [%IA] per tumor mass (assumed as 100 mg, 
due to an approximate calculated volume of the tumors at the start of the therapy); (ii) the adsorbed 
radiation dose in tumor xenografts was assessed for a sphere of 100 mg using the Unit Density Sphere 
Model from RADAR [23]; (iii) The absorbed dose (mGy/MBq) was calculated by multiplying the 
AUC (s; normalized to 1 MBq ID) with the S-value (mGy/MBq·s); and (iv) the dose (mGy) was 
calculated by multiplying the absorbed dose (mGy/MBq) with the amount of injected radioactivity. 
2.10. Statistical Significance 
Significance of the survival time and tumor growth delay was calculated by the performance of the 
t-test (Microsoft Excel). All analyses were two-tailed and considered as type 3 (two sample unequal 
variance). A p-value < 0.05 was considered statistically significant. 
3. Results and Discussion 
3.1. Production and Purification of 
149
Tb 
149
Tb was produced by proton-induced spallation of tantalum targets at ISOLDE/CERN on a  
zinc-covered gold foil containing isobar and pseudo-isobar nuclides of mass number 149. Upon arrival 
at PSI (~4 h after the end of collection) ~40 MBq 
149
Tb, ~5 MBq 
149
Gd, ~0.4 MBq 
145
Eu (from  
α-decay of 149Tb), ~70 MBq 133mCe, ~15 MBq 133Ce and ~350 MBq 133La were detected. The mass  
133 pseudo-isobars appear at mass 149 as monoxide molecular ions. The radioactive solution which 
was obtained after dissolution of the zinc-layer was loaded on column I for chromatographic 
separation of 
149
Tb. The elution was accomplished with a diluted solution of α-HIBA within 
only 25 min. The 
149
Tb (~29 MBq, corresponding to 73% of total radioactivity) was isolated in a 
volume of 1.65 mL free of radioactive impurities. Under these isocratic elution conditions an excellent 
separation of 
149
Tb and 
149
Gd was achieved (Figure 2). Further radiolanthanide impurities such as 
145
Eu, 
133m
Ce, 
133
Ce and 
133
La as well as stable Zn were retained on the chromatographic column I and 
eluted afterwards using a higher concentrated α-HIBA solution for regeneration of the column. 
After concentration of the 
149
Tb-solution by adsorption at the cation exchanger of the second 
column, the product was obtained within 25 min as 
149
Tb-L-lactate (0.4 M, pH 4.7) in a small volume 
of only 225 μL. Addition of 375 μL MilliQ water resulted in a solution of 0.15 M sodium L-lactate 
with a physiological osmolarity of ~300 mOsm. Determination of radioactivity revealed a total yield of 
~25 MBq 
149
Tb containing ~88 kBq 
149
Gd—which decays via electron capture and γ-ray emission—as 
the only detectable radionuclide impurity generated by the decay of 
149
Tb after separation on column I. 
The total yield of the separation process was ~63% (corresponding to a ~94% decay-corrected yield) 
and the whole isolation process including measurement of the single elution fractions was 
accomplished within 145 min. The L-lactate-based physiological formulation was suitable not only for 
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the direct performance of radiolabeling of cm09 but allowed even in vitro and in vivo application 
without further purification steps. 
Figure 2. Elution profile of chromatographic column I showing separation of 
149
Tb (■, red) 
from 
149
Gd (●, blue). 
 
In comparison to our previous study [7] where we used 
149
Tb for radiolabeling directly after elution 
from the first column in the α-HIBA solution (~0.15 M), the purification process was optimized in the 
present study. The advantages were two-fold: Firstly, using the second chromatographic column 
allowed concentration of the radioactivity in a smaller volume which was favorable for subsequent 
radiolabeling steps and in vivo application. Secondly, the elution was carried out with a solution of  
L-lactate providing 
149
Tb in a more physiological solution compared to the α-HIBA solution which was 
employed in our previous studies. 
3.2. Radiosynthesis of 
149
Tb-cm09 and Stability in Blood Plasma 
Radiolabeling of cm09 (18 nmol) with 
149
Tb (25 MBq) resulted in a product peak of the 
radiolabeled product with a retention time (Rt) of 19.5 min. The chromatogram was equal to what was 
previously obtained with the 
161
Tb-labeled match (
161
Tb-cm09) [9]. On the other hand injection of free 
149/161
Tb(III) was eluted almost with the front (Rt = 3 min). These findings confirmed the identity of the 
product peak as 
149
Tb-cm09 which was obtained with a radiochemical purity of >96% with only 
insignificant traces of free 
149
Tb(III). 
Incubation of 
149
Tb-cm09 (1.0–1.2 MBq/nmol) in blood plasma at 37 °C revealed high stability (>98%) 
of the folate radioconjguate over at least 4 hours. These findings were expected as it was previously 
shown that 
161
Tb-cm09 was completely stable in human blood plasma over several days [7,9]. 
3.3. In Vitro Application of 
149
Tb-cm09 
In vitro cell viability assays were performed to investigate the effect of 
149
Tb-cm09. FR-positive KB 
tumor cells were incubated with increasing radioactivity concentrations of 
149
Tb-cm09. It was found 
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that the viability of the KB cells was inhibited in an activity-dependent manner (Figure 3). Application 
of a low radioactivity concentration of 
149
Tb-cm09 (0.5 kBq/mL) resulted in an only 20%-reduction of 
the tumor cell viability. However, a 1,000-fold higher radioactivity concentration (500 kBq/mL) 
resulted in an almost complete loss of KB cell viability. Addition of excess folic acid to block cell 
surface exposed FRs abolished the effect of 
149
Tb-cm09 completely even at high radioactivity 
concentrations. Under these conditions tumor cells grew normally and comparably to untreated control 
cells (Figure 3). These findings clearly indicated a FR-specific effect of 
149
Tb-cm09. 
Figure 3. In vitro viability of KB tumor cells is reduced upon exposure to increasing 
radioactivity concentrations of 
149
Tb-cm09 (red bars). Incubation of cells with excess folic 
acid to block FRs protected KB cells from the 
149
Tb-cm09-induced inhibitory effect 
(yellow bars). Exposure of cells to unlabeled cm09 (100 nM to 10 μM) had no effect on 
cell growth (data not shown). 
 
3.4. Therapy Study in Tumor-Bearing Mice Using 
149
Tb-cm09 
The therapy study in KB tumor-bearing nude mice showed significant tumor growth delay (TGD) 
in 
149
Tb-cm09 treated mice compared to untreated control mice (Figure 4A). The tumor growth delay 
index for a 5-fold increased tumor volume compared to the tumor volume at the beginning of the study 
(TGDI5) reached a value of 1.5 (p = 0.04) for mice of group B which were treated with 2.2 MBq  
149
Tb-cm09. This means a 1.5-fold higher value than for untreated control mice (TGDI5 = 1). In mice 
of group C, which received 3.0 MBq of 
149
Tb-cm09, the TGDI5 was even 2.0-fold (p = 0.01) increased 
compared to the TGDI5 of untreated controls. At day 21 when the first control mouse had to be 
euthanized due to an oversized tumor the average relative tumor volume (RTV) was significantly 
smaller in treated mice of group B (p = 0.01) and group C (p = 0.001) compared to the tumor volume 
of untreated control mice (group A). At this time point of the study tumor growth was inhibited  
by 62% (group B) and 85% (group C), respectively, indicating a dose-dependent therapeutic efficacy of 
149
Tb-cm09. The average survival time was increased by 45% (30.5 d, p = 0.01) in mice of group B and 
by 105% (43 d, p = 0.004) in mice of group C compared to control mice (group A, 21 d) (Figure 4B). 
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Figure 4. Results of FR-targeted radionuclide α-therapy using 149Tb-cm09 in KB  
tumor-bearing mice. (A) Graph of the average relative tumor volume (RTV) of mice from 
each group (n = 4) during the time period when at least 3 mice were still alive; (B) Survival 
curves of mice from each group (group A: 21 d; group B: 30.5 d and group C: 43 d). 
 
Analysis of blood plasma parameters (BUN, ALP and TBIL) did not reveal significant changes  
(p > 0.05) among control mice and mice treated with 
149
Tb-cm09 (Table 2). This analysis indicated 
unimpaired renal and hepatobiliar function. Hence, it can be concluded that acute radiotoxic effects to 
the kidneys and the liver were not experienced by FR-targeted α-radionuclide therapy over the whole 
time of this study which lasted for 35 days. More detailed studies to investigate effects of 
149
Tb-cm09 
on kidney function will be necessary since undesired side-effects on the long-term cannot be excluded 
based on the examinations performed herein. 
Table 2. Results of plasma analysis at day 14 and before terminal (in parentheses);  
(BUN = blood urea nitrogen, ALP = alkaline phosphatase, TBIL = total bilirubin). 
 BUN [mmol/L] ALP [U/L] TBIL [μmol/L) 
Group A 7.0 ± 1.8 (4.1 ± 0.5) 77 ± 10 (99 ± 16) 6.5 ± 2.5 (6.3 ± 1.0) 
Group B 4.6 ± 0.6 (4.7 ± 0.4) 67 ± 5 (119 ± 7) 7.6 ± 4.7 (6.0 ± 1.0) 
Group C 5.2 ± 1.3 (5.9 ± 1.4) 75 ± 14 (73 ± 21) 7.0 ± 0.8 (5.0 ± 1.0) 
Overall the present results outperformed our previous data which were obtained upon 
administration of two injections of 
149
Tb-cm09 at low quantities of radioactivity (1.1 MBq and  
1.3 MBq, respectively) [7]. Compared to our previous therapy study, the present study design differed 
in that the mice received the whole amount of radioactivity in a single injection of either 2.2 MBq 
149
Tb-cm09 (group B) or 3.0 MBq 
149
Tb-cm09 (group C). 
Beyer et al. conducted an experiment where 
149
Tb-labeled rituximab (5.5 MBq per mouse) was 
investigated in a leukemia animal model using SCID mice with an intravenous graft of Daudi cells [5]. 
Their aim was to examine the efficacy of 
149
Tb-rituximab to specifically kill circulating single cancer 
cells or small cell clusters in vivo. The therapy was started within 3 days upon intravenous 
xenografting of a lethal number of Daudi cells when most of the tumor cells were expected to be still 
in circulation [5]. Whereas untreated control mice had to be euthanized within the first 37 days a 
tumor-free survival was found for over 120 d in almost 90% of the 
149
Tb-rituximab treated animals. 
Since application of the same amount of unlabeled rituximab did not show a therapeutic effect, the 
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favorable outcome of this study could be ascribed to the α-radionuclide therapy [5]. In the present 
study injection of 
149
Tb-cm09 reduced tumor growth of solid KB xenografts and increased the survival 
time significantly in mice of both treated groups (B and C) compared to untreated control mice (group A). 
These excellent results complement those of Beyer et al. by demonstrating the therapeutic potential of 
149
Tb. However, our study design differed from that of Beyer et al. in three respects. (i) Instead  
of using an established antibody, we employed a small-molecular weight folate conjugate (cm09)  
as a targeting agent which previously proved the promising potential to be used for therapeutic  
purposes [15]; (ii) The amount of injected radioactivity was 2.2 MBq and 3.0 MBq, respectively, in 
our study compared to 5.5 MBq which were used in the study of Beyer et al. [5]; (iii) Finally the tumor 
mouse model which was used in our study was based on solid tumor xenografts of a human cervical 
cancer cell line while Beyer et al. used a tumor mouse model with circulating leukemia cells. 
3.5. Dosimetric Calculations 
In order to obtain an idea about the radioactive dose burden of 
149
Tb-cm09 to KB tumor xenografts 
a dose estimation was made while taking only the self-radiation dose into account. According to the 
AUC obtained from tissue distribution data in mice injected with 
161
Tb-cm09 [7] and the S-value of 
149
Tb listed for a sphere of 100 mg an absorbed dose of 8.67 Gy/MBq was estimated for KB tumor 
xenografts. This resulted in an absorbed dose of ~19 Gy (group B) and ~26 Gy (group C) in tumors 
upon a single injection of 2.2 MBq and 3.0 MBq of 
149
Tb-cm09, respectively. 
Recently, we peformed a preclinical therapy study with 10 MBq of 
161
Tb-cm09 using the same KB 
tumor mouse model [9]. In that case the dose to the tumor was calculated to a value of ~33 Gy and the 
corresponding TGDI5 reached a value of ~2.2. In the present study the TGDI5 for 
149
Tb-cm09 was  
~1.6 (2.2 MBq, ~19 Gy) and ~2.0 (3.0 MBq, ~26 Gy) indicating a slightly improved effect of the  
α-radionuclide therapy. However, for an exact comparison of α- and β−/Auger-radionuclide therapy it 
would be necessary to perform a site-by-site study using 
149
Tb-folate and 
161
Tb-folate with an activity 
that results in the same calculated dose to the tumor. 
4. Conclusions 
In this study the potential of α-radionuclide therapy in general and of 149Tb in particular was 
demonstrated using a folate-based biomolecule. Application of 
149
Tb-cm09 was well-tolerated in mice 
and treated KB tumor xenografts efficiently. The experiments revealed significant tumor growth delay 
and an increased survival time of mice treated with 
149
Tb-cm09 compared to untreated control mice. 
However, further studies will be required to investigate potential advantages of FR-targeted  
α-radionuclide therapy over β−-radionuclide therapy with regard to tumor response and potential 
damage to the kidneys. 
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